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The f o r m a t i o n  a n d  e l i m i n a t i o n  o f  s u l p h a m e t h o x a z o l e  h y d r o x y l a m i n e  in r e la t io n  to the  
p h a r m a c o k in e t i c s  o f  the  p a r e n t  c o m p o u n d  an d  its N 4- a c e ty l  m e ta b o l i t e  w e re  i n v e s t i ­
ga ted  in s ix  h e a l th y  s u b je c t s  a f t e r  a s in g le  o ra l  d o s e  o f  8 0 0  m g  s u l p h a m e t h o x a z o l e .  
The a p p a r e n t  h a l f - l iv e s  o f  s u l p h a m e t h o x a z o l e  a n d  its m e t a b o l i t e s  w e re  a p p r o x i m a t e l y  
10 h, in d ic a t iv e  o f  f o r m a t i o n  r a t e - l im i t e d  m e t a b o l i s m .  T h e  m e a n  r e s id e n c e  t im e  o f  the  
h y d r o x y l a m in e  m e t a b o l i t e  w a s  5 .5  ±  1.5 h. T h e  re n a l  c l e a r a n c e  o f  s u l p h a m e t h o x a z o l e  
h y d r o x y l a m in e  w a s  4 .3 9  ±  0.91 1 I f '. T h e  u r in a ry  r e c o v e r y  o f  s u l p h a m e t h o x a z o l e  
a c c o u n te d  fo r  16.5 ±  5 .5 %  o f  the  d o s e ,  N - i - a c e ty l - s u lp h a m e th o x a z o le  fo r  4 6 .2  ±  6 .6 %  
and the  h y d r o x y l a m i n e  m e t a b o l i t e  fo r  2 .4  ±  0 .8 % .  T h e  r e m a i n i n g  3 5 %  o f  the  d o s e  
was u n a c c o u n t e d  for. A c e t y l a t o r  p h e n o t y p e  w a s  d e t e r m i n e d  u s in g  s u lp h a d im id in e .  
The rena l  e x c r e t i o n  o f  s u l p h a m e t h o x a z o l e  h y d r o x y l a m i n e  w a s  1.9 ±  0 .9 %  in s lo w  
a c e ty la to r s  (// =  3) a n d  2 .8  ±  0 .3 %  in fa s t  a c e ty l a to r s  (/? =  3); fo r  N 4- a c e ty l -  
s u l p h a m e t h o x a z o l e  the  v a lu e s  w e re  48  ±  6 %  a n d  4 4  ±  8 % ,  r e s p e c t iv e ly .  S u l p h a ­
m e th o x a z o le  is m e t a b o l i z e d ,  a l t h o u g h  to a l im i te d  e x te n t ,  to a h y d r o x y l a m i n e  m e t a b o ­
lite. T h i s  m e t a b o l i t e  m a y  be  im p o r t a n t  fo r  the  p a th o g e n e s i s  o f  a d v e r s e  r e a c t io n s .
Keywords s u l p h a m e t h o x a z o l e  p h a r m a c o k i n e t i c s  s u l p h a m e t h o x a z o l e  h y d r o x y l a m i n e
Introduction
he high incidence o f side-effects to sulpham ethoxa- 
zole (SM X) in individuals infected with the human 
im m unodeficiency virus (HIV) [1] has renewed inter­
est in the m etabolism  of this drug. It is postulated 
that the hydroxylam ine metabolite (N O H -SM X ) is 
critical in the pathogenesis o f adverse reactions to 
sulphonamides [2 -7 ]. In HIV seropositive individ­
uals, the detoxification capacity for reactive products 
of sulphonam ide m etabolism  seem s to be decreased  
owing to glutathione deficiency [8]. Although NOH- 
SMX may be an important m etabolite, in vivo data on 
its information and elim ination are limited [6, 9, 10J.
Sulpham ethoxazole hydroxylam ine (N O H -SM X ) 
results from the hydroxylation o f the para-amino 
group o f SM X, a cytochrom e P450-dependent reac­
tion [6]. Besides hydroxylation, the para-amino group 
o f SM X can also be acetylated resulting in the paral­
lel formation o f Na-acetyl-sulpham ethoxazole (N 4- 
A cSM X ) [11]. N-acetyl transferase exhibits a marked 
genetic polymorphism and the rate o f acétylation o f  
som e sulphonam ides (sulphadim idine, sulphamer- 
azine, sulphadiazine, and sulphapyridine) depends on 
the acetylator phenotype [11]. A prominence o f the 
slow  acetylator phenotype has been reported in 
patients with hypersensitivity reactions to sulphona­
mides [12]. However, for some sulphonam ides (like 
SM X) slow  and fast acetylators have not been 
distinguished [11].
In th is study we document the formation and e lim i­
nation o f sulpham ethoxazole hydroxylam ine in re-
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lation to the kinetics o f  the parent com pound  and the 
Na-acetyl metabolite  in healthy subjects (three slow, 
three fast acetylators).
M ethods
Subjects
Six Caucasians (four males, two females) ranging in 
age from 23 to 50 years (mean 34 years) participated 
after approval o f  the study by the Ethics Comm ittee  
o f  our university hospital. Written informed consent 
was obtained from all participants. All subjects were 
drug-free and healthy by history, physical exam ina­
tion and routine biochemical assessment.  An 800 m s  
dose of  su lpham ethoxazole  was adminis tered orally 
in two gelatine capsules on an empty stomach after
an overnight fasting.
Sampling procedures
Blood samples were obtained by fingertip puncture at
1, 2, 4, 6, 8, 10, 12, 24, 32, 36, and 48 h after drug 
administration. Plasma was separated immediately  by 
centrifugation and stored at - 2 0 °  C until analysis. 
Urine was collected over 96 h and three 5 ml aliquots 
were stored immediately  at - 2 0 °  C until analysis.
Acetylator phenotype
Volunteers were phenotyped using sulphadim idine  as 
described previously [13].
Chemicals
SM X and Na-AcSM X were obtained from Hoffmann 
LaRoche, Mijdrecht,  the Netherlands. N O H -SM X  
was obtained from Synthon BV, Nijmegen, the 
Netherlands. All other chemicals  were of  analytical 
purity and were obtained from commeric ia l  sources.
jjg m l-1, respectively, in p lasma and 0.10 pg ml-1 for 
all com pounds  in urine. The hydroxylam ine  m etabo­
lite was stable in anaerobic  p lasm a and urine.
Sample preparation
After thawing, the sample (100 pi) was diluted with 
900 pi 0.33 M tr ichloroacetic  acid, centr ifuged at 
3000 g, and the supernatant injected onto the column.
Data analysis
Renal c learances were calculated from urinary recov­
eries o f  the com pounds  (corrected for molecular  
weight) divided by the corresponding  A U C values. 
Curve litting to a one com partm ent  model with first 
order drug absorption was carried out using the Medi- 
ware'K com puter  program 15. AUC values were ca lcu­
lated using the linear trapezoidal rule with 
extrapolation to infinity using C(last)/k . Oral c lear­
ance (C L 0) of  SM X  and its mean residence time 
(MRT) were calculated by standard m ethods [14].
Statistics
The M ann-W hitney  test was used to com pare  results. 
Pearson correlation coefficients were calculated. Dif­
ferences were considered  significant when P < 0.05.
Results
Plasma concentrat ions and renal excretion rates of 
SM X, N O H -S M X  and Na-AcSM X in a representative 
subject are shown in Figure 1. Mean pharmacokinetic  
parameters  are sum m arised  in Table 1.
The elimination half-life o f  SM X  was 9.5 h while 
the half-lives of N 4-A cSM X  and N O H -S M X  were
11.1 and 11.2 h, respectively (NS). The mean resi­
dence time of  SMX was 14.0 h and those of  N4-
Drug analysis
SM X and its metabolites were assayed by h.p.l.c. 
using a Spectra Physics SP8810 pump (Eindhoven, 
The Netherlands),  a 757 Separations u.v. detector 
(Hendrik  Ido Ambacht,  The Netherlands) and a C 8 
(5 um) column (Synthon, Nijmegen, The Netherlands) 
(250 m m  x 4 mm i.d.). The mobile phase consisted of 
45 ml of  a mixture of  20 g orthophosphoric  acid and 
5 g te tram ethylam monium chloride in 1 1 water, 45 ml 
d im ethy lform am ide  and 180 ml acetonitrile, adjusted 
to 1 1 with water. The mobile phase was degassed 
with helium before use. The How rate was 1.5 ml 
m in-1. Detection was at 271 nm. The retention times 
of N O H -SM X , SM X, and N4-ACSMX were 8 .6 , 10.1 
and 13.3 min, respectively, and the chrom atographic  
peaks were identified using authentic standards. Intra- 
and interday variation in the assay of both samples 
and standards was <5%. Quantitat ion limits, de te r­
mined with a signal-to-noise ratio o f  3, for SM X, N 4- 
A cSM X , and N O H -SM  were 0.0055, 0.01, and 0.01
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Figure 1 Plasma concentrations and renal excretion rates 
o f  sulphamethoxazole (SM X) and its Na-acetyl 
(Na-AcSM X) and hydroxylamine metabolites (NO H -SM X)  
in one subject after an 800 mg oral dose o f  
sulphamethoxazole.
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Table 1 Mean (± s.d. and range) o f  pharmacokinetic parameters describing the fate o f  
sulphamethoxazole in six healthy subjects
SMX N 4-AcSM X N O H -SM X
P a ra m e te r M ean  ± s.d. (Range) M ean ± s.d. (Range) Mean  ± s.d. (Range)
C max (Mg ml"') 46.9 ± 8.7 (3 5 .6 -6 1 .4 ) 8.1 ± 1.1 (6 .5-9 .1  ) 0.3 ± 0.1 (0 .2 -0 .4 )
/max (h) 0.7* (0 .6- 1.6 ) 5.7* (5 .1 -9 .0 ) 2.9* (2 . 1- 8 . 1)
ti/,.: (h) 9.5 ± 0.7 (8 .7 -1 0 .5 ) 11.1 ± 1.4 (9 .3 -1 3 .4 ) 1 1.2 ± 1.2 (9 .8 -1 2 .2 )
MRT (h) 14.0 ± 0.9 (1 2 .8 -1 5 .4 )
MRT (in) (h) 5.5 ± 1.5 (2 .8- 6 .7) 5.2 ± 1.7 (3 .2 -6 .4 )
AUC (mg I-1 h) 675 ± 102 (5 0 1 -8 1 3 ) 189± 29 (1 6 1 -2 2 7 ) 6 ± 1 (4 -7 )
CL0 (1 h"1) 1.2 ± 0.2 ( 1.0- 1.6 )
C L r (1 I r 1) 0.22 ± 0.05 (0 .1 4 -0 .2 8 ) 2.45 ± 0.35 (1 .9 1 -2 .9 7 ) 4 .39 ± 0.91 (3 .4 4 -5 .5 1 )
/4e(°°) (%) 16.5 ± 5.5 (8 .3 -2 3 .4 ) 46.2 ± 6.6 (3 6 .9 -5 4 .4 ) 2.4 ± 0.8 (0 .9 -3 .2 )
* Median.
Cm ax = Maximum plasma drug concentration, /max time at which C max occurs, t,l2- = plasma duration half- 
life, MRT = mean residence time, MRT(m) = mean residence time o f  metabolite after administration o f  
drug, (MRT(m) = MRTm-MRT), MRT = MRT parent compound, AUC = area under plasma 
concentration-time curve, CLU = oral clearance (D ose/A U C ), CLr = renal clearance (/\e(°°)/AUC ), Ac  (<») 
= amount excreted in urine (molar).
AcSM X and N O H -S M X  formed from SM X were 5.5 
and 5.1 h, respectively.
The urinary recoveries o f  parent drug and m e tabo ­
lites were similar in all subjects. Sulpham ethoxazole  
accounted for 16.5 ± 5.5% (percentage ± s.d.) o f  the 
dose, N 4-A cSM X , for 46.2 ±  6 .6 %, and N O H -SM X , 
for 2.4 ± 0.8%. Three subjects acetylated sulphadimi- 
dine rapidly and three slowly. Renal excretion of 
N O H -SM X  accounted for 1.9 ± 0.9% of  the dose of 
SMX in the slow acetylators and 2.8 ± 0.3% in the 
fast acetylators. For N 4-ACSMX, the values were 48 
± 6 % and 44 ± 8 %, respectively.
The clearance (metabolic-  and renal clearance) of 
SMX was 1.21 ± 0.21 1 h_ l . The mean renal clearance 
of SM X was 0.22 ± 0.05 1 h“ 1, which differed 
significantly from that o f  N4-ACSMX (2.45 ±
0.35 1 h " 1) and N O H -S M X  (4.39 ± 0 .9 1  1 h r 1) (paired 
/-test, P < 0.05). The renal clearance o f  SM X  but not 
of its metabolites  correlated with the urine pH (SMX, 
r = 0.91, all samples).
Discussion
Metabolism
After a single 800 mg oral dose o f  su lpham ethoxa­
zole, the renal excretion of  SM X, Na-AcSMX, and 
N O H -SM X  accounted for 65% of  the dose. The oral 
c learance o f  SM X (1.2 1 h_ l) was much greater  than 
its renal c learance (0.2 1 h_l). The fate o f  35% of  the 
dose is unknown.
The hydroxylam ine  metabolite  accounted for 2.4% 
of the recovered dose of  SM X, a figure in agreement 
with those reports by others [6 , 9]. Since N O H -SM X  
is unstable and can be oxidised to nitroso derivates 
|15J, it is possible that its urinary recovery is less 
than the amount formed in the liver. However,  under 
physiological conditions glutathione prevents the auto­
oxidation of  N O H -S M X  [15].
Mechanism o f  renal clearance
After g lom erular  filtration, SM X undergoes net pas­
sive reabsorption while data for N 4-ACSMX when 
corrected for p lasma binding indicate that this c o m ­
pound undergoes net active excretion [16]. Urine flow 
and pH govern passive reabsorption and influence the 
renal excretion of  SM X  but not that o f  N 4-ACSMX. 
This difference in excretion is discernable from 
respective excretion rate-time profiles. Thus, the 
excretion rate-time curve of N 4-AC-SMX was smooth 
and parallel to the corresponding  plasma concentra- 
tion-time curve, while that of  SM X had an irregular 
profile. The shape of  the excretion rate-time profile of 
N O H -S M X  was similar to that o f  N 4-ACSMX and, in 
a separate experiment,  it was shown that the excre ­
tion of N O H -S M X  is not dependent on urine pH (data 
not shown). This suggests that N O H -S M X  undergoes 
limited passive tubular reabsorption. The high renal 
c learance rates of  N 4-ACSMX and N O H -S M X  c o m ­
pared with that of  SM X are associated with similar 
apparent half-lives.
Acetyl at or pheno typ e
A previous study indicated that SM X clearance is 
unrelated to acetylator  phenotype [16], and we now 
show that the excretion of N4-ACSMX is s imilar in 
both fast and slow acetylators of sulphadimidine. 
Overrepresentat ion  of  the slow acetylator phenotype 
has been reported in patients with sulphonamide 
hypersensitivity  reactions [12]. Thus, it was sug­
gested that in slow acetylators more of  the parent 
drug may be available for metabolism by cytochrom e 
P450 to the hydroxylam ine metabolites [12]. H o w ­
ever, our data do not indicate an increased hydroxy­
lamine formation in slow sulphadimidine acetylators, 
a lthough the num ber  of subjects studied was limited.
This study has docum ented  the formation and renal 
excretion of the N 4-acetyl and hydroxylam ine 
metabolites  of su lpham ethoxazole  in healthy subjects.
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Su lpham ethoxazo le  hydroxylam ine  may be critical in contribution o f  /V-hydroxylation to the metabolism of 
the pathogenesis  o f  adverse reactions although the su lpham ethoxazo le  was found to be small.
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